In their recent article published in Journal of Clinical Oncology, Tewari et al¹ highlighted that in the GOG-0218 trial, neither first-line bevacizumab concurrent with chemotherapy nor bevacizumab concurrent with chemotherapy plus maintenance significantly improved overall survival (OS) compared with chemotherapy alone, even though bevacizumab administered throughout treatment has prolonged median progression-free survival (PFS) by approximately 4 months.² Moreover, the authors demonstrated that germ line or somatic mutations in BRCA1/2 genes were prognostic, but not predictive, of bevacizumab efficacy.

中文翻译：

---

贝伐单抗作为卵巢癌患者的维持治疗：等待BRCA测试。

在他们发表在最近的一篇文章临床肿瘤学杂志，特瓦里等人¹强调的是，在GOG-0218试验中，既不一线贝伐单抗并发与化疗也不贝伐单抗一致与化疗加维护单独化疗相比显著改善的总体存活（OS） ，即使在整个治疗期间服用贝伐单抗将中位无进展生存期（PFS）延长了约4个月。²此外，作者证明BRCA1 / 2基因的种系或体细胞突变是贝伐单抗疗效的预后指标，但不能预测。